HONG KONG—Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced the successful completion of a pre-set interim analysis in its Phase III clinical study. The study combines anlotinib with penpulimab as a first-line treatment for advanced hepatocellular carcinoma (HCC), achieving the optimal efficacy thresholds for its primary endpoints: progression-free survival (PFS) and overall survival (OS).
The interim analysis results indicate that the combination therapy significantly reduced the risk of disease progression or death in patients compared to sorafenib, a standard treatment. Furthermore, it demonstrated a notable prolongation of both PFS and OS, offering new hope for patients with advanced HCC. The safety profile of the combination was found to be in line with known risks, with no new safety signals detected, which is a testament to the robustness of the treatment.
This indication would mark the 10th for anlotinib and the 5th for penpulimab in China, expanding their therapeutic footprint in the country. Sino Biopharmaceutical is expected to make a market filing in the near term, reflecting the significance of these clinical findings and their potential impact on the treatment landscape for HCC.- Flcube.com
